Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX001899 (Sosimerasib) QTc Study in Healthy Subjects
NCT06473948Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of sosimerasib in solid tumor (4 arms), sponsored by Jemincare. Primary endpoint: Change in time-matched QTc intervals at 48 hours. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
sosimerasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06473948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06473948.